Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vildagliptin Monotherapy in Drug-Naive T2DM
NCT00120536Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2005
- Primary completion
- Jul 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of vildagliptin in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Novartis. Primary endpoint: Change from baseline in HbA1c at 24 weeks. Started Jun 2005; status: completed.
02
Drugs
vildagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00120536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00120536.